Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Angiogenesis is essential to human biology and of great clinical significance. Excessive or reduced angiogenesis can result in, or exacerbate, several disease states, including tumor formation, exudative age-related macular degeneration (AMD) and ischemia. Innovative drug delivery systems can increase the effectiveness of therapies used to treat angiogenesis-related diseases. AREAS COVERED: This paper reviews the basic biology of angiogenesis, including current knowledge about its disruption in diseases, with the focus on cancer and AMD. Anti- and proangiogenic drugs available for clinical use or in development are also discussed, as well as experimental drug delivery systems that can potentially improve these therapies to enhance or reduce angiogenesis in a more controlled manner. EXPERT OPINION: Laboratory and clinical results have shown pro- or antiangiogenic drug delivery strategies to be effective in drastically slowing disease progression. Further research in this area will increase the efficacy, specificity and duration of these therapies. Future directions with composite drug delivery systems may make possible targeting of multiple factors for synergistic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Foreign body reaction to biomaterials
Anderson, J. M., Rodriguez, A., & Chang, D. T. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2007.11.004 · Cited by 5,138 · cited 1×
“One concern with implantable reservoirs is the potential for local inflammation or foreign body response [65,66].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 3×
“Tarrytown, NY) [28] Binds/sequesters VEGF-A and PLGF Fusion protein Wet AMD Cetuximab (Erbitux , is a registered trademark of ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY) [29,30] Anti-EGFR Chimeric IgG1 mAb mCRC, head and neck cancer in KRAS-wt patients”
BackgroundTumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549 · cited 1×
“Nanocapsules have a lipophilic interior consisting of the lipophilic block of a copolymer, which serves as a drug reservoir and is surrounded by a hydrophilic core, whereas polymersomes are composed of bilayers, similar to liposomes [101].”
BackgroundMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 2×
“Many angiogenic inhibitors have been developed, and several, such as bevacizumab [25], ranibizumab [26], pegaptanib [27], aflibercept [28], cetuximab [29,30], panitumumab [31], trastuzumab [32,33], gefitinib [34], erlotinib [35], sorafenib [36,37], sunitinib [38,39], temsirolimus [40] and everolimus (Table 1) [41], ha…”
BackgroundTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501 · cited 1×
“Polymeric gene delivery has gained attention as an alternative to viral gene delivery, which suffers from limited cargo capacity, immune response, and the possibility of insertional mutagenesis [111].”
BackgroundPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 4×
“Many angiogenic inhibitors have been developed, and several, such as bevacizumab [25], ranibizumab [26], pegaptanib [27], aflibercept [28], cetuximab [29,30], panitumumab [31], trastuzumab [32,33], gefitinib [34], erlotinib [35], sorafenib [36,37], sunitinib [38,39], temsirolimus [40] and everolimus (Table 1) [41], ha…”
BackgroundInfluentialVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · cited 3×
“Many angiogenic inhibitors have been developed, and several, such as bevacizumab [25], ranibizumab [26], pegaptanib [27], aflibercept [28], cetuximab [29,30], panitumumab [31], trastuzumab [32,33], gefitinib [34], erlotinib [35], sorafenib [36,37], sunitinib [38,39], temsirolimus [40] and everolimus (Table 1) [41], ha…”
BackgroundVEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 1×
“Newer treatments include VEGF-TRAP, a recombinant protein that targets VEGF rather than the VEGF receptor [162], and a recently completed Phase III trial has found it to be comparably effective to ranibizumab.”
BackgroundLutolf, M. P., Lauer-Fields, J. L., Schmoekel, H. G., Metters, A. T., Weber, F. E., Fields, G. B., & Hubbell, J. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737381100 · Cited by 1,508 · cited 1×
“Furthermore, drug-loaded depots can themselves be substrates for cell growth, as in the case of GF-loaded hydrogels [60-62].”
BackgroundGaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Polymeric micelles—A new generation of colloidal drug carriers
Jones, M.-C., & Leroux, J.-C. (1999) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00039-9 · Cited by 1,256 · cited 1×
“Self-assembly of amphiphiles into colloids causes micelle formation, in which a lipophilic core is isolated from the surrounding aqueous phase by an external hydrophilic shell or corona [89].”
BackgroundFolkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186 · cited 6×
“Inc., San Francisco, CA) [25] Anti-VEGF receptor Humanized mAb mCRC, NSCLC, advanced breast cancer”
BackgroundInfluentialDobrovolskaia, M. A., Aggarwal, P., Hall, J. B., & McNeil, S. E. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800032f · Cited by 1,022 · cited 1×
“One difficulty with particulate-based systems, however, is their tendency to be cleared relatively quickly through the liver, spleen and kidneys in a size-dependent manner [84,85].”
BackgroundAge-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959 · cited 1×
“Dry AMD results from atrophy of retinal pigment epithelium (RPE), which leads to photoreceptor atrophy [45].”
BackgroundHydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence
Grizzi, I., Garreau, H., Li, S., & Vert, M. (1995) · Biomaterials · doi:10.1016/0142-9612(95)93258-f · Cited by 895
Discher, D. E., & Ahmed, F. (2006) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.8.061505.095838 · Cited by 844
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
Teesalu, T., Sugahara, K. N., Kotamraju, V. R., & Ruoslahti, E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908201106 · Cited by 812 · cited 1×
“Peptide sequences that cause tumor penetration have been identified [154], and efforts are being made to use this principle to enhance the effect of peptides to tumor endothelium [155].”
BackgroundMoulton, K. S., Vakili, K., Zurakowski, D., Soliman, M., Butterfield, C., Sylvin, E., Lo, K.-M., Gillies, S., Javaherian, K., & Folkman, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730843100 · Cited by 652 · cited 1×
“Angiogenesis is also critical in pathologic states such as psoriasis [5], atherosclerosis [6,7], rheumatoid arthritis [8,9], diabetes [10], cancer [11] and ocular neovascularization [12] in age-related macular degeneration (AMD) and diabetic retinopathy.”
BackgroundA combinatorial polymer library approach yields insight into nonviral gene delivery
Green, J. J., Langer, R., & Anderson, D. G. (2008) · Accounts of Chemical Research · doi:10.1021/ar7002336 · Cited by 579
Self-citationConcurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis
Patil, S. D., Papadmitrakopoulos, F., & Burgess, D. J. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.10.013 · Cited by 230 · cited 1×
“In one case, VEGF and dexamethasone were released slowly from PLGA particles to encourage angiogenesis while minimizing local inflammation [76].”
BackgroundBressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205 · cited 5×
“Neovascular AMD results from an interplay of genetic, metabolic and environmental factors [46].”
BackgroundInfluential
Cited by
Drug delivery systems and materials for wound healing applications
Saghazadeh, S., Rinoldi, C., Schot, M., Kashaf, S. S., Sharifi, F., Jalilian, E., Nuutila, K., Giatsidis, G., Mostafalu, P., Derakhshandeh, H., et al. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.008 · Cited by 842
Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment
Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., Jin, G., Lu, T. J., Genin, G. M., & Xu, F. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00094 · Cited by 825
Organ-on-a-chip platforms for studying drug delivery systems
Bhise, N. S., Ribas, J., Manoharan, V., Zhang, Y. S., Polini, A., Massa, S., Dokmeci, M. R., & Khademhosseini, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.004 · Cited by 381
Self-citationPeplow, P., & Martinez, B. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.295271 · Cited by 19
“The damage to the retina causes central vision loss and eventual loss of sight if untreated (Bhise et al., 2011; Farnoodian et al., 2017).”
Background
Metadata
- Authors
- Bhise, N. S., Shmueli, R. B., Sunshine, J. C., Tzeng, S. Y., & Green, J. J.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2011-02-22
- Volume
- 8
- Issue
- 4
- Pages
- 485-504
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2111044102
- Cited by
- 65
- References
- 26
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.